Literature DB >> 19046911

Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.

Ayman M Noreddin1, Walid F El-Khatib, Jason Aolie, Ahmed H Salem, George G Zhanel.   

Abstract

OBJECTIVE: To compare the probability of target attainment (PTA) for macrolides and ketolides against penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae in both serum and epithelial lining fluid (ELF) of patients with community-acquired pneumonia (CAP).
METHODS: Monte Carlo simulations were used to assess the attainment of the bacterial eradication-linked pharmacodynamic index of the free drug area under the concentration-time curve over 24 hours to minimum inhibitory concentration (fAUC(0-24)/MIC90) by azithromycin, clarithromycin, and telithromycin, at therapeutic doses, against penicillin-susceptible, intermediate, and resistant S. pneumoniae.
RESULTS: In serum, azithromycin and clarithromycin were found to have a probability of attaining the recommended fAUC(0-24)/MIC90 ratio of 30 in 50.2% and 74.6%, respectively, of CAP patients with penicillin-intermediate strains, and a probability of 36.9% and 60.7%, respectively, in cases of penicillin-resistant strains. Telithromycin maintained a probability of reaching the fAUC(0-24)/MIC90 ratio of 30 in serum and ELF in 89.1% of CAP patients, regardless of the penicillin resistance of the strain.
CONCLUSIONS: Clarithromycin results in a higher PTA than azithromycin in the treatment of penicillin-susceptible S. pneumoniae, but both of these agents exhibit a decreasing efficacy as S. pneumoniae penicillin resistance increases. When compared to clarithromycin and azithromycin, telithromycin maintains higher PTA in CAP patients with penicillin-resistant strains of S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046911     DOI: 10.1016/j.ijid.2008.08.016

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

Review 1.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

2.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.

Authors:  Yi Zheng; Shu-Ping Liu; Bao-Ping Xu; Zhong-Ren Shi; Kai Wang; Jin-Bin Yang; Xin Huang; Bo-Hao Tang; Xing-Kai Chen; Hai-Yan Shi; Yue Zhou; Yue-E Wu; Hui Qi; Evelyne Jacqz-Aigrain; A-Dong Shen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 4.  Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Authors:  Ashit Trivedi; Richard E Lee; Bernd Meibohm
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

5.  A clinical pathway for community-acquired pneumonia: an observational cohort study.

Authors:  Christopher R Frei; Allison M Bell; Kristi A Traugott; Terry C Jaso; Kelly R Daniels; Eric M Mortensen; Marcos I Restrepo; Christine U Oramasionwu; Andres D Ruiz; William R Mylchreest; Vanja Sikirica; Monika R Raut; Alan Fisher; Jeff R Schein
Journal:  BMC Infect Dis       Date:  2011-07-06       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.